2026-04-13T05:52:46Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/122702025-10-24T10:38:14Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Bielack, Stefan
author
soussain, carole
author
Fox, Christopher Paul
author
Houillier, Caroline
author
Murciano, Thais
author
Osborne, Wendy
2025-10-24T10:38:14Z
2025-10-24T10:38:14Z
2024-11-25T13:38:42Z2024-11-25T13:38:42Z2024-10-02
http://hdl.handle.net/11351/12270
Consensus; Glucarpidase; Methotrexate toxicityConsens; Glucarpidasa; Toxicitat del metotrexatConsenso; Glucarpidasa; Toxicidad del metotrexatoHigh-dose methotrexate (HDMTX) is used in the treatment of a range of adult and childhood cancers. Although HDMTX can provide effective anti-tumor activity with an acceptable safety profile for most patients, delayed methotrexate elimination (DME) develops in a minority of patients receiving HDMTX and may be accompanied by renal dysfunction and potentially life-threatening toxicity. A panel of European physicians with experience in the use of HDMTX as well as of glucarpidase convened to develop a series of consensus statements to provide practical guidance on the prevention and treatment of DME, including the use of glucarpidase. Robust implementation of supportive measures including hyperhydration and urine alkalinization emerged as critical in order to reduce the risk of DME with HDMTX treatment, with leucovorin rescue critical in reducing the risk of DME complications. Early recognition of DME is important to promptly implement appropriate treatment including, intensified hydration, high-dose leucovorin and, when appropriate, glucarpidase.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Càncer - Tractament
Decisió de grup
Antimetabòlits - Ús terapèutic
DISEASES::Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Antimetabolites::Antimetabolites, Antineoplastic
Other subheadings::Other subheadings::/therapeutic use
PSYCHIATRY AND PSYCHOLOGY::Behavior and Behavior Mechanisms::Psychology, Social::Group Processes::Consensus
ENFERMEDADES::neoplasias
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::antimetabolitos::antimetabolitos antineoplásicos
Otros calificadores::Otros calificadores::/uso terapéutico
PSIQUIATRÍA Y PSICOLOGÍA::conducta y mecanismos de la conducta::psicología social::procesos de grupo::consenso
A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion